NEJM - PCV

"Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera"

"CONCLUSIONS

In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera. (Funded by Incyte and others; RESPONSE ClinicalTrials.gov number,NCT01243944.)"

http://www.nejm.org/doi/full/10.1056/NEJMoa1409002